ConductScience.org, home

Paper31623402

Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies.

Kohl V and 10 others. Cancers (Basel), 2019. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies. Papers, record 31623402. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31623402

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2019
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
0.54
iCite
Revised in PubMed
2020-09-28
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kohl VVanessa
2Flach JJohanna
3Naumann NNicole
4Brendel SSusanne
5Kleiner HHelga
6Weiss CChristel
7Seifarth WWolfgang
8Nowak DDaniel
9Hofmann WKWolf-Karsten
10Fabarius AAlice
11Popp HDHenning Dhttps://orcid.org/0000-0003-0090-0204

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
DJCLS 14 R/2017José Carreras Leukämie-StiftungPubMed

Source PubMed

Download CSV of grants

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119230772Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.Lancet Oncol2009https://conductscience.org/library/papers/19230772PubMed
221941284A decade of exploring the cancer epigenome - biological and translational implications.Nat Rev Cancer2011https://conductscience.org/library/papers/21941284PubMed
322455312Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors.J Med Chem2012https://conductscience.org/library/papers/22455312PubMed
423786647Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study.Br J Haematol2013https://conductscience.org/library/papers/23786647PubMed
523881923BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.Clin Cancer Res2013https://conductscience.org/library/papers/23881923PubMed
623118055Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.Cancer Res2012https://conductscience.org/library/papers/23118055PubMed
721821475The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.Mol Oncol2011https://conductscience.org/library/papers/21821475PubMed
820348135Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme.Nucleic Acids Res2010https://conductscience.org/library/papers/20348135PubMed
919372272Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites.Nucleic Acids Res2009https://conductscience.org/library/papers/19372272PubMed
1022377908Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors.Int J Cancer2012https://conductscience.org/library/papers/22377908PubMed
1126594843Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.Nat Med2015https://conductscience.org/library/papers/26594843PubMed
1216532500Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.Cancer2006https://conductscience.org/library/papers/16532500PubMed
1329878489Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.Am J Hematol2018https://conductscience.org/library/papers/29878489PubMed
1418626472Single-strand break repair and genetic disease.Nat Rev Genet2008https://conductscience.org/library/papers/18626472PubMed
1525735917Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.Leuk Res2015https://conductscience.org/library/papers/25735917PubMed
1619153658DNA repair in mammalian cells: Base excision repair: the long and short of it.Cell Mol Life Sci2009https://conductscience.org/library/papers/19153658PubMed
1726529666Trypan Blue Exclusion Test of Cell Viability.Curr Protoc Immunol2015https://conductscience.org/library/papers/26529666PubMed
1828588020Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Blood2017https://conductscience.org/library/papers/28588020PubMed
1924450632PARP inhibitors for anticancer therapy.Biochem Soc Trans2014https://conductscience.org/library/papers/24450632PubMed
2017991682Quantitative analysis of the binding affinity of poly(ADP-ribose) to specific binding proteins as a function of chain length.Nucleic Acids Res2007https://conductscience.org/library/papers/17991682PubMed

See all 46 referencesDownload CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
41446759Contrasting roles of APE1 and APE2 in genome maintenance, cancer development, and therapeutic targeting.NAR Cancer2025https://conductscience.org/library/papers/41446759PubMed
41008918PARP3 Promotes AML Progression via Activation of PI3K/AKT/mTOR Signaling.Cancers (Basel)2025https://conductscience.org/library/papers/41008918PubMed
39175540Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia.Front Pharmacol2024https://conductscience.org/library/papers/39175540PubMed
35091444Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.Clin Cancer Res2022https://conductscience.org/library/papers/35091444PubMed
35065680Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.J Hematol Oncol2022https://conductscience.org/library/papers/35065680PubMed
34976824Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019.Front Oncol2021https://conductscience.org/library/papers/34976824PubMed
34703267New Horizons for the Roles and Association of APE1/Ref-1 and ABCA1 in Atherosclerosis.J Inflamm Res2021https://conductscience.org/library/papers/34703267PubMed
33868289Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.Front Immunol2021https://conductscience.org/library/papers/33868289PubMed
33039802Treatment of human cells with 5-aza-dC induces formation of PARP1-DNA covalent adducts at genomic regions targeted by DNMT1.DNA Repair (Amst)2020https://conductscience.org/library/papers/33039802PubMed
33036275DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets.Cancers (Basel)2020https://conductscience.org/library/papers/33036275PubMed
32547565Base Excision Repair in the Immune System: Small DNA Lesions With Big Consequences.Front Immunol2020https://conductscience.org/library/papers/32547565PubMed

Download CSV of cited by

Genes44

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
APEX1328PubTator's text mininghttps://conductscience.org/library/genes/328NCBI Gene
ASXL1171023PubTator's text mininghttps://conductscience.org/library/genes/171023NCBI Gene
ASXL255252PubTator's text mininghttps://conductscience.org/library/genes/55252NCBI Gene
BCOR54880PubTator's text mininghttps://conductscience.org/library/genes/54880NCBI Gene
BCS1L617PubTator's text mininghttps://conductscience.org/library/genes/617NCBI Gene
CBL867PubTator's text mininghttps://conductscience.org/library/genes/867NCBI Gene
CD33945PubTator's text mininghttps://conductscience.org/library/genes/945NCBI Gene
CD34947PubTator's text mininghttps://conductscience.org/library/genes/947NCBI Gene
CEBPA1050PubTator's text mininghttps://conductscience.org/library/genes/1050NCBI Gene
CSF21437PubTator's text mininghttps://conductscience.org/library/genes/1437NCBI Gene
CSF31440PubTator's text mininghttps://conductscience.org/library/genes/1440NCBI Gene
DNMT11786PubTator's text mininghttps://conductscience.org/library/genes/1786NCBI Gene
DNMT3A1788PubTator's text mininghttps://conductscience.org/library/genes/1788NCBI Gene
ETV62120PubTator's text mininghttps://conductscience.org/library/genes/2120NCBI Gene
EZH22146PubTator's text mininghttps://conductscience.org/library/genes/2146NCBI Gene
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
GATA12623PubTator's text mininghttps://conductscience.org/library/genes/2623NCBI Gene
GATA22624PubTator's text mininghttps://conductscience.org/library/genes/2624NCBI Gene
GUSB2990PubTator's text mininghttps://conductscience.org/library/genes/2990NCBI Gene
IDH13417PubTator's text mininghttps://conductscience.org/library/genes/3417NCBI Gene

See all 44 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31623402

GET https://conductscience.org/api/papers/v1/31623402/references?page=2